Roivant Sciences

Zest Health, LLC is a Chicago-based company that develops a mobile application designed to enhance healthcare navigation for consumers, employers, and providers. The application features several tools, including "Talk to Me," which provides immediate phone access to medical experts; "Schedule Me," for booking medical appointments; "Inform Me," which offers health-related information similar to WebMD; and "Track Me," which allows users to store their electronic health records. Zest Health's solution focuses on strategic buying, access to healthcare professionals, and preventative care and disease management programs. As a subsidiary of Roivant, Zest also operates Zest Dermatology, a virtual clinic that specializes in high-quality, cost-effective care for patients with conditions like eczema and psoriasis. By partnering with health plans, employers, and dermatologists, Zest aims to optimize dermatology care and reduce specialty drug costs, while participating in initiatives to improve patient outcomes.

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Its investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.

Lokavant is an information technology company that specializes in providing clinical trial intelligence. It offers real-time monitoring and anticipatory analytics aimed at enhancing the management of clinical trials. By utilizing advanced analytics and visualization techniques, Lokavant enables rigorous analysis and proactive risk management, simplifying the monitoring process for clinical trials. The company's services include real-time visualizations, risk alerts, and a combination of artificial intelligence and human insights, all designed to improve the efficiency and effectiveness of clinical research.

Medallion is a company that offers a network management platform tailored for the healthcare industry, focusing on simplifying the complex processes of licensing, credentialing, and payer enrollment. Founded in 2020 by Derek Lo and based in San Francisco, California, Medallion's all-in-one platform addresses the logistical challenges that healthcare providers and telemedicine companies face, enabling them to minimize time spent on administrative tasks. Key features of the platform include facilities for new licensing and renewals, primary source verification, continuing medical education tracking, and document management. By streamlining these processes, Medallion allows healthcare professionals to concentrate more on patient care rather than paperwork.

Gen-t is a platform capable of providing the map of genomic research. Gen-t was founded in 2021 and was headquartered in Sao Paulo, Brazil.

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Its investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.

Silicon Therapeutics is a drug design and development company that specializes in computational drug discovery. The company employs a physics-driven approach to drug design, integrating chemistry and biology research to create novel small molecule therapeutics. Its unique platform is designed to target challenging protein targets that are biologically and genetically validated but have historically been difficult to address. By simulating interactions and conformational behaviors of biological molecules using the laws of physics, Silicon Therapeutics enhances the understanding of the relationship between protein conformations and biological outcomes, ultimately advancing the field of biotechnology and expanding the possibilities in drug discovery.

Datavant, Inc. is a health data platform company based in San Francisco, California, founded in 2017. The company specializes in aggregating and analyzing biomedical data using machine learning to enhance the efficiency of drug development. It focuses on improving the clinical trial process by employing artificial intelligence and organizing healthcare data to derive actionable insights for trial design and interpretation. By facilitating secure and accessible data connectivity, Datavant enables over 60 million healthcare records to be exchanged among thousands of organizations, including more than 70,000 hospitals and clinics. The company serves the clinical development and commercial pharmaceutical sectors, as well as researchers, and aims to improve patient outcomes while protecting patient privacy through its innovative platform.

Patara Pharma, LLC operates in the healthcare industry focusing on the biotechnology business. The company is engaged in developing a new therapy for the treatment of allergic and immunologic diseases and conditions that affect orphan patient populations, providing patients with the drug required for their treatment. It was incorporated in 2013 and is based in San Diego, California.

Datavant, Inc. is a health data platform company based in San Francisco, California, founded in 2017. The company specializes in aggregating and analyzing biomedical data using machine learning to enhance the efficiency of drug development. It focuses on improving the clinical trial process by employing artificial intelligence and organizing healthcare data to derive actionable insights for trial design and interpretation. By facilitating secure and accessible data connectivity, Datavant enables over 60 million healthcare records to be exchanged among thousands of organizations, including more than 70,000 hospitals and clinics. The company serves the clinical development and commercial pharmaceutical sectors, as well as researchers, and aims to improve patient outcomes while protecting patient privacy through its innovative platform.

Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). They believe that Arbutus' comprehensive HBV pipeline of drugs and drug candidates optimally positions us to transform the HBV treatment landscape and to capitalize on the HBV global market opportunity. They are developing a portfolio of drug candidates with multiple mechanisms of action that They believe will result in a combination therapy to cure HBV. Specifically, They seek to effect a cure by targeting the three pillars necessary to develop a curative regimen for HBV. This includes suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence.